Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Do you know your liver cancer risk?
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
Karen’s tribute to Gavin on his 21st birthday. This sweet boy died, donated his organs, and Karen carries his liver.
Hepatitis C can lead to a variety of complications such as cirrhosis, portal hypertension, liver cancer, and liver transplant.
Hepatitis C patients have a higher risk factor for liver cancer and other associated liver conditions.
HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.
A look at two recent cancer studies. One showing an increased hepatitis prevalence in cancer patients; the other looks at high fiber diets.
A study found that people who had the largest increase in whole grain lowered their liver cancer risk by nearly 40 percent.
Highlights some of the latest hepatitis C and liver disease research.
Find out if you are at risk for liver cancer even if your hepatitis C treatment was successful and you are virus-free.
Seventy percent of liver cancer patients had either a partial response or stable disease.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.